Edition:
India

Novartis AG (NOVN.S)

NOVN.S on Virt-X Level 1

91.43CHF
18 Jun 2019
Change (% chg)

CHF1.75 (+1.95%)
Prev Close
CHF89.68
Open
CHF89.42
Day's High
CHF91.69
Day's Low
CHF89.42
Volume
5,161,482
Avg. Vol
5,053,458
52-wk High
CHF96.20
52-wk Low
CHF71.84

About

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines... (more)

Overall

Beta: 1.06
Market Cap(Mil.): CHF226,655.00
Shares Outstanding(Mil.): 2,527.38
Dividend: 2.85
Yield (%): 3.12

Financials

  NOVN.S Industry Sector
P/E (TTM): 16.89 31.89 36.81
EPS (TTM): 5.31 -- --
ROI: 13.18 12.41 12.05
ROE: 21.05 13.73 16.96

NEWSMAKER-France's Sanofi bets on new CEO to drive sluggish drug sales

ZURICH, June 7 In veteran drug salesman Paul Hudson, Sanofi's 100,000-plus employees are getting a new chief executive who relishes a good commercial fight.

07 Jun 2019

Drugmaker Sanofi hires Hudson from Novartis as CEO

PARIS Sanofi has poached Paul Hudson from Novartis to replace Chief Executive Olivier Brandicourt who will retire in September, France's biggest drugmaker said on Friday, helping send its shares almost 5 percent higher.

07 Jun 2019

UPDATE 3-Drugmaker Sanofi hires Hudson from Novartis as CEO

* Hudson from Novartis to join Sanofi from Sept. 1 * Current CEO Brandicourt to retire * Shares up almost 5 percent (Adds share price, comment) By Matthias Blamont PARIS, June 7 Sanofi has poached Paul Hudson from Novartis to replace Chief Executive Olivier Brandicourt who will retire in September, France's biggest drugmaker said on Friday, helping send its shares almost 5 percent higher. Hudson, who is British, will take over on Sept. 1,

07 Jun 2019

CORRECTED-UPDATE 2-Drugmaker Sanofi appoints Novartis' Hudson as CEO

PARIS, June 7 Sanofi has appointed Novartis executive Paul Hudson to replace CEO Olivier Brandicourt who will retire in September, France's biggest drugmaker said on Friday.

07 Jun 2019

Swiss drugmaker Novartis names new drug division head

ZURICH Swiss pharmaceuticals giant Novartis named Marie-France Tschudin head of its main drugs business after its previous manager, Paul Hudson, was poised to take the CEO position at French drugmaker Sanofi.

07 Jun 2019

Swiss drugmaker Novartis names new drug division head

ZURICH, June 7 Swiss pharmaceuticals giant Novartis named Marie-France Tschudin head of its main drugs business after its previous manager, Paul Hudson, was poised to take the CEO position at French drugmaker Sanofi .

07 Jun 2019

Exclusive: Sanofi poised to appoint Novartis' Hudson as CEO

PARIS Sanofi is poised to appoint Paul Hudson, a top executive with Switzerland's Novartis, to become the French drugmaker's next CEO from Sept. 1, a source familiar with the decision told Reuters on Thursday.

07 Jun 2019

Exclusive: Sanofi poised to appoint Novartis' Hudson as CEO

PARIS Sanofi is poised to appoint Paul Hudson, a top executive with Switzerland's Novartis, to become the French drugmaker's next CEO from Sept. 1, a source familiar with the decision told Reuters on Thursday.

07 Jun 2019

Swiss stocks - Factors to watch on June 3

ZURICH/BERLIN June 3 The Swiss blue-chip SMI was seen opening down 0.4 percent at 9,482 points on Monday, according to premarket indications by bank Julius Baer .

03 Jun 2019

Novartis hopes Kisqali data will help narrow gap to blockbuster rival

ZURICH Novartis has released data showing sharply improved overall survival rates for its breast cancer drug Kisqali, which the Swiss drugmaker hopes will help it chip away at the dominance of Pfizer's blockbuster Ibrance.

01 Jun 2019

Earnings vs. Estimates